Search
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigationalAgalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater b...
Products: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/MLMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.
Categories: Drugs for Obstructive Airway DiseasesProducts: NUCALA POWDER FOR SOLUTION FOR INJECTION 100mg, Nucala 100mg Powder for Solution for InjectionNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Categories: Integrin Receptor AntagonistProducts: Tysabri Concentrate for Solution for Infusion 300mg/15mlFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigationalFremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsProducts: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5MLPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.
Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody InteractionsProducts: KEYTRUDA SOLUTION FOR INFUSION 25MG/ML, Keytruda 100mg Solution for InfusionSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigationalSecukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions ...
Products: SCAPHO (POWDER FOR SOLUTION FOR INJECTION), Fraizeron 150mg Powder for Solution for InjectionVigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual … [L13616] It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA.
Products: Vigabatrin for Oral Solution, Vigabatrin for oral solution USP, 500 mgImiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human ...
Products: (Imiglucerase) 400U Powder for solution for injectionTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigationalTeriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...
Products: FORTEO 250 UG SOLUTION FOR INJECTION, KAULIV 20 micrograms/80 microliters solution for injectionTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.
Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsProducts: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL